Has Iqra Iqbal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $756 in general payments to Iqra Iqbal, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Iqra Iqbal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Iqra Iqbal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Iqra Iqbal, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1104353614

Payments from drug & device makers

$756in general payments, 2019–2025

Across 11 payments — averaging $68.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kyowa Kirin, Inc.$225
Genentech USA, Inc.$133
Medtronic$131
Pfizer$115
Johnson & Johnson$84
Dexcom, Inc.$32
plus $36 from 2 others

What the payments were for

Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kyowa Kirin, Inc.	3	$225
Genentech USA, Inc.	1	$133
Medtronic	1	$131
Pfizer	1	$115
Johnson & Johnson	1	$84
Dexcom, Inc.	2	$32
Carl Zeiss Meditec USA, Inc.	1	$22
Smith+Nephew	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$756 in reported general payments places this provider in the 35th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri →

Medicare billing

Part B allowed, 2024

$31,975

Medicare patients

119

Services billed

356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	12	$15,728

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Saint Louis

Thomas NickolasSaint Louis$945K
Anne GoldbergSaint Louis$830K
Janet McGillSaint Louis$828K
Julie SilversteinSaint Louis$536K
Sandeep DhindsaSaint Louis$173K
Maamoun SalamSaint Louis$170K
Michael WhyteSaint Louis$133K
Fumihiko UranoSaint Louis$122K
Farid RomanSaint Louis$62K
Kathryn DiemerSaint Louis$57K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →